An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

Avian influenza: A vaccine for a deadly emergent strain A vaccine candidate to treat a deadly subtype of avian influenza was shown to induce protective antibodies in initial clinical trials. As of March 2017, avian influenza strain A/H7N9 has killed 497 people since 2013, with 1349 confirmed cases....

Full description

Bibliographic Details
Main Authors: Adam D. DeZure, Emily E. Coates, Zonghui Hu, Galina V. Yamshchikov, Kathryn L. Zephir, Mary E. Enama, Sarah H. Plummer, Ingelise J. Gordon, Florence Kaltovich, Sarah Andrews, Adrian McDermott, Michelle C. Crank, Richard A Koup, Richard M. Schwartz, Robert T. Bailer, Xiangjie Sun, John R. Mascola, Terrence M. Tumpey, Barney S. Graham, Julie E. Ledgerwood
Format: Article
Language:English
Published: Nature Publishing Group 2017-06-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-017-0016-6

Internet

https://doi.org/10.1038/s41541-017-0016-6

Similar Items